NetScientific (STU:NTK1) Debt-to-Asset : 0.09 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is NetScientific Debt-to-Asset?

NetScientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.90 Mil. NetScientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €1.40 Mil. NetScientific's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was €26.85 Mil. NetScientific's debt to asset for the quarter that ended in Jun. 2023 was 0.09.

NetScientific Debt-to-Asset Historical Data

The historical data trend for NetScientific's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific Debt-to-Asset Chart

NetScientific Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.07

0.06

0.03

0.04

NetScientific Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.04	0.09

Competitive Comparison of NetScientific's Debt-to-Asset

For the Biotechnology subindustry, NetScientific's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetScientific's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NetScientific's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NetScientific's Debt-to-Asset falls into.

NetScientific Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NetScientific's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.307	+	1.135)	/	33.291
	=	0.04

NetScientific's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.895	+	1.398)	/	26.854
	=	0.09

NetScientific (STU:NTK1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NetScientific Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NetScientific's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NetScientific (STU:NTK1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (STU:NTK1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NSCI:UK

Address

20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG

Website

https://www.netscientific.net

NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (STU:NTK1) Headlines

No Headlines